Recognition and management of complications of new recreational drug use
暂无分享,去创建一个
[1] Patrick M. O'Malley,et al. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2004. , 2003 .
[2] Paul J. Wang,et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. , 2002, Mayo Clinic proceedings.
[3] J. Olney,et al. NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia , 1995, Neuropsychopharmacology.
[4] A. Giannini,et al. Acute ketamine intoxication treated by haloperidol: a preliminary study. , 2000, American journal of therapeutics.
[5] H. Kalant,et al. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[6] M. Aminoff. Neurology and General Medicine , 2007 .
[7] K. Miotto,et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. , 2001, The American journal on addictions.
[8] H. Druid,et al. Flunitrazepam: an evaluation of use, abuse and toxicity. , 2001, Forensic science international.
[9] R. de la Torre,et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.
[10] M. J. Cupp,et al. Use and Abuse of Flunitrazepam , 1998, The Annals of pharmacotherapy.
[11] A. Weinbroum,et al. A Risk-Benefit Assessment of Flumazenil in the Management of Benzodiazepine Overdose , 1997, Drug safety.
[12] J. Kraner,et al. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). , 2001, Journal of analytical toxicology.
[13] Liesbeth Reneman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[14] M. Colado,et al. The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.
[15] L. Quang,et al. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. , 2000, Pediatric emergency care.
[16] Jones,et al. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications , 1999, Alimentary pharmacology & therapeutics.
[17] M. Spitz,et al. Volatile nitrites. Use and adverse effects related to the current epidemic of the acquired immune deficiency syndrome. , 1985, The American journal of medicine.
[18] D. Aunis,et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator γ‐hydroxybutyrate , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] B. Goldberger,et al. Recreational drugs. Current trends in the 90s. , 1998, Clinics in laboratory medicine.
[20] H. Pal,et al. Ketamine dependence. , 2002, Anaesthesia and intensive care.
[21] F. Romanelli,et al. Poppers: Epidemiology and Clinical Management of Inhaled Nitrite Abuse , 2004, Pharmacotherapy.
[22] R. Hoffman,et al. The “ecstasy” hangover: Hyponatremia due to 3,4-Methylenedioxymethamphetamine , 2002, Journal of Urban Health.
[23] M. Shannon. Methylenedioxymethamphetamine (MDMA, "Ecstasy"). , 2000, Pediatric emergency care.
[24] U. McCann,et al. (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies , 2000, Neuropsychobiology.
[25] G. Galloway,et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. , 1997, Addiction.
[26] K. Graeme. New drugs of abuse. , 2000, Emergency medicine clinics of North America.
[27] C. McKay,et al. Ketamine abusers presenting to the emergency department: a case series. , 2000, The Journal of emergency medicine.
[28] R. Clark,et al. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. , 2001, The Journal of emergency medicine.
[29] U. McCann,et al. (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.
[30] J. Dyer,et al. Gamma-hydroxybutyrate withdrawal syndrome. , 2001, Annals of emergency medicine.
[31] Retraction Kiehntopf,et al. Retraction , 1997, Concurr. Comput. Pract. Exp..
[32] K. Jansen,et al. The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence , 2001, Journal of psychoactive drugs.
[33] N. Benowitz,et al. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids , 2000 .
[34] M. Parr,et al. Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. , 2002, QJM : monthly journal of the Association of Physicians.
[35] M. Forsling,et al. Low-dose MDMA (“ecstasy”) induces vasopressin secretion , 1998, The Lancet.
[36] G. Goodwin,et al. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”) , 1995, Psychopharmacology.
[37] A. Mallick,et al. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. , 1997, Journal of accident & emergency medicine.
[38] J. Li,et al. Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions. , 2000, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[39] F. Romanelli,et al. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[40] P. Rogers,et al. MDMA ('ecstasy') and other 'club drugs'. The new epidemic. , 2002, Pediatric clinics of North America.
[41] C. Morgan,et al. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. , 2000, Addiction.
[42] K. Nicholson,et al. GHB: a new and novel drug of abuse. , 2001, Drug and alcohol dependence.
[43] Stephen W. Smith,et al. Adverse events, including death, associated with the use of 1,4-butanediol. , 2001, The New England journal of medicine.
[44] E. Guérot,et al. Acute benzodiazepine withdrawal delirium after a short course of flunitrazepam in an intensive care patient. , 2000, Annales de medecine interne.
[45] S. Dawling,et al. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.
[46] J. Woods,et al. Abuse liability of flunitrazepam. , 1997, Journal of clinical psychopharmacology.
[47] B. O'Connor. Hazards associated with the recreational drug 'ecstasy'. , 1994, British journal of hospital medicine.
[48] M. Sivilotti,et al. Pentobarbital for severe gamma-butyrolactone withdrawal. , 2001, Annals of emergency medicine.
[49] J. Knochel,et al. Medical progress: Heat stroke , 2002 .
[50] S. Doyon. The many faces of ecstasy. , 2001, Current opinion in pediatrics.
[51] M. Verbaten. Specific memory deficits in ecstasy users? The results of a meta‐analysis , 2003, Human psychopharmacology.
[52] L. Johnston,et al. Monitoring the Future National Survey Results on Drug Use, 1975-2001. Volume 1: Secondary School Students, 2001. , 2002 .
[53] W. Lynn,et al. Gamma butyrolactone (GBL) withdrawal syndromes. , 2001, Psychosomatics.
[54] Metaphors, Misuse, and Misconceptions , 2003, Science.